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2214-3882/ª 2016 Editorial Office of A
the CC BY-NC-ND license (http://creaAbstract Bone metastasis of non-seminomatous germ cell tumors (NSGCT) of the testes is a
rare event and even more uncommon at initial presentation. Generally, bone lesions are
discovered in the presence of concurrent retroperitoneal lymph node or visceral disease. How-
ever, in this case, a 37 years old male complaining of a growing testicular mass was found to
have isolated bone metastasis with associated caudaequina syndrome without apparent
abnormal findings on initial CT scans. Continued neurologic symptoms prompted further eval-
uation with MRI, which demonstrated multiple sites of bone metastasis without evidence of
retroperitoneal lymph node or visceral organ involvement. This case represents a rare clinical
presentation and disease manifestation of NSGCT.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).105
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1121. Introduction
Bone metastasis at initial presentation of non-seminomatous
germ cell tumor (NSGCT) of the testes is an uncommon
event, as it is usually associated with concurrent retroperi-
toneal lymph node or visceral disease. We present a case ofbe Blvd Unit 1373, Houston,
on.org (N. Navai).
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tivecommons.org/licenses/by-nc-NSGCT with an isolated bone metastasis that was not
documented on initial staging CT that caused caudaequina
syndrome, without any lymph node or visceral involvement
and only discovered after additional imaging with magnetic
resonance imaging (MRI).
2. Case report
A 37-year-old man presented to our center with a 6-month
history of a growing right testicular mass. One week prior to
presentation at our center the mass had become acutely
painful prompting the patient to seek treatment at an119
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AJUR120_proof ■ 30 August 2016 ■ 2/4outside emergency center. A right-sided mass concerning
for malignancy was found on testicular ultrasound and
the patient was referred to our center for further evalua-
tion. He reported right testicular pain, left buttock
pain radiating to his left lateral thigh, constipation, and
difficulty urinating. He denied nausea, vomiting, fever,
personal history of cryptorchidism, trauma, sexually
transmitted infections, or urinary tract infections. His past
surgical history was unremarkable. He denied family history
of testicular cancer. Physical exam revealed a well-
circumscribed, hard mass involving the right testicle,
without tenderness to palpation or evidence of tracking
along the spermatic cord. The left testicle was palpably
normal. Serum a-fetoprotein (AFP), b-human chorionic
gonadotropin (b-hCG) and lactic dehydrogenase (LDH)
levels were elevated at 2613 ng/mL, 7.1 mIU/mL, and
1130 IU/L, respectively. All other routine laboratories were
normal. A computed tomography (CT) of the abdomen and
pelvis with and without contrast showed a mass in the right
testicle consistent with NSGCT, without evidence of retro-
peritoneal lymphadenopathy or metastatic disease. He was
prescribed a bowel regimen and hydrocodone for pain
management, and was scheduled for orchiectomy.
He returned 3 days later with worsening testicular pain,
urinary retention and constipation, which the patient
attributed to pain medications. At that time he underwent
emergent radical right inguinal orchiectomy. Pathology
demonstrated a 12 cm  9 cm  6 cm NSGCTwith extensive
necrosis, composed of 85% immature teratoma, 10% yolk
sac tumor, and 5% embryonal carcinoma, with invasion of
the tunica vaginalis (pT2 cN0 cM0 SX; Stage IB) (Fig. 1).
There was no evidence of lymphovascular infiltration and
all margins were negative. He was discharged on post-
operative day 1 with routine follow-up.
The patient returned on postoperative day 2, with
continued constipation, urinary retention and severe rectal
pain. He also continued to have left buttock pain radiating
down the left thigh. He had no focal deficits on neurologic
exam. Abdominal X-ray showed no evidence of ileus or
obstruction. MRI of the pelvis with and without contrast was
obtained and showed a large infiltrative mass concerningFigure 1 Histologic section of testicular mass. Teratomatous
component (arrow) with areas reminiscent of immature neural
tissue.
Please cite this article in press as: Biebighauser KC, et al., Non-semino
rare clinical presentation, Asian Journal of Urology (2016), http://dx.for metastasis in the sacrum as well as the left acetabulum
(Fig. 2). Scattered foci of metastatic disease were promi-
nent in the ilea, bilateral proximal femora, and lumbar
vertebrae. There was no evidence of retroperitoneal
lymphadenopathy or visceral organ metastasis. A percuta-
neoussacral biopsy was obtained that confirmed metastatic
NSGCT (Fig. 3).
The patient was reclassified as stage IIIC with poor risk
and immediately started on etoposide, cisplatin, and
bleomycin (BEP), with dexamethasone. He had significant
improvement of constipation, urinary retention and pain
after initiation of chemotherapy. Due to the rapid tissue
response to chemotherapy, radiation therapy to the spinal
lesion was withheld and planned only in the event that
chemoreduction did not provide an adequate symptomatic
response. After two cycles of BEP the patient developed
characteristic post-inflammatory pulmonary changes on
chest CT likely secondary to bleomycin. He was switched to
taxol, ifosfamide, and cisplatin (TIP), receiving three cy-
cles. The patient responded well to chemotherapy initially,
but became resistant by the third cycle of TIP per mea-
surement of tumor markers. His LDH and b-hCG normalized,
but his AFP remained elevated at 16.6 ng/mL 8 months
after initial diagnosis. Although there is no evidence of
additional metastases, his bone disease remains present
and he is currently undergoing high dose chemotherapy and
stem cell rescue.Figure 2 (A) CT of the pelvis without visible sacral lesion. (B)
MRI of the pelvis with visible sacral lesion. (arrow).
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Figure 3 Sacral biopsy. Histologic section demonstrating
cells consistent with metastasis of non-seminomatous germ
cell tumors.
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The most common malignancy in men aging 15e40 years is
germ cell tumor of the testes [1]. Metastatic bone disease is
relatively uncommon, and is usually found in the setting of
retroperitoneal lymph node and/or visceral metastases [2].
Isolated bone metastases, such as this case, is an excep-
tionally rare presentation.
A few large studies have been done to characterize pa-
tients with germ cell tumors and bone metastases. Jamal-
Hanjani et al. [2] reviewed 2550 patients with germ cell
tumors (GCTs), 19 of which had bone metastasis at either
diagnosis (13/19) or relapse (6/19). The majority of the
patients with bone metastases (11/19) were of non-
seminomatous origin. Concurrent metastasis to other sites
were found in 63% (12/19) of patients, while only 37% (7/
19) of patients had isolated bone metastases. The most
common site of bone metastasis in this group was the
vertebral column, with symptomatic spinal cord compres-
sion in 4/19 patients, and caudaequina syndrome in 2/19
patients. Another study by Hitchins et al. [3] reviewed 297
patients with metastatic GCTs, of which 3% had clinically
detectable bone involvement at presentation, and 9% at
relapse. All of the patients with bone metastasis at pre-
sentation had concurrent metastatic disease in the lymph
nodes, lungs, or mediastinum. Symptomatic spinal cord
compression occurred in two patients. All affected patients
exhibited localized bone pain. A third study by Oechsle
et al. [4] was more selective in its patient population, but
produced similar results after assessing 434 patients with
poor prognosis GCTs who underwent high-dose chemo-
therapy. In this group, 9% (40/434) of patients presented
with primary bone metastases. They noted that bone
metastases were more common with primary mediastinal
non-seminomatous tumors, yolk sac tumor histology, and
concurrent liver metastases. According to the international
germ cell tumor consensus classification, the presence of
non-pulmonary visceral metastases in NSGCT places pa-
tients into a poor prognostic category, with a 48% 5-
year survival rate [5]. Well-established risk factors for
metastatic disease in NSGCT include location and size of
the tumor, multiplicity, tumor extension, pT category,Please cite this article in press as: Biebighauser KC, et al., Non-semino
rare clinical presentation, Asian Journal of Urology (2016), http://dx.histological type, the presence or absence of carcinoma in
situ/testicular intraepithelial neoplasia (CIS/TIN) and the
presence of absence of lymphovascular invasion, with the
latter being the most significant risk factor for advanced
disease [1].
A small number of case reports have been published,
demonstrating other patients with NSGCTs who presented
with isolated bony metastases in the absence of other nodal
or visceral involvement [6e9]. Metastasis of NSGCT usually
occurs via lymphatic vessels, spreading first to retroperi-
toneal lymph nodes then sequentially to extranodal sites.
Our patient lacked this typical metastatic pattern. This
implies that the typical nodal pattern for spread of testic-
ular NSGCT is not absolutely necessary for the disease to
metastasize to bone.
Assessment of our patient’s risk factors for metastatic
disease also highlights some unique features of this case.
Histological examination showed a large tumor size with
yolk sac tumor histology, which increased his risk for met-
astatic disease according to the study by Oechsle et al. [4].
However, the pathology report of our patient showed no
identifiable lymphovascular invasion. This demonstrates
extratesticular metastases cannot be ruled out, even in the
setting of seemingly confined disease.
At initial presentation the patient complained of pain in
his left buttock radiating down his left thigh, and bowel and
bladder dysfunction, which are consistent with caudae-
quina syndrome. However, he was never noted to have
sensory or motor deficits throughout his course, nor did he
have bony tenderness or pain on exam. At the time of
diagnosis, his urinary retention and constipation were
thought to be attributed to pain and narcotic use since the
staging CT was normal. As mentioned above, very few cases
of symptomatic spinal cord involvement at diagnosis of
NSGCT have been reported. Although it is rare, symptoms
of potential spinal cord compression should raise awareness
and prompt evaluation for metastatic lesions given the af-
finity of NSGCT to the vertebrae in such cases, and its
associated poor prognosis.
Additionally, bone metastasis was not detected during
routine staging for our patient. The European Germ Cell
Cancer Consensus group currently recommends staging of
NSGCT based on serum tumor markers, orchiectomy with
histopathology, and CT of the chest, abdomen, and pelvis.
MRI is generally reserved for patient with contraindications
to CT. Positron emission tomography (PET) scan has been
shown to have low diagnostic yield over CT or MRI in the
setting of NSGCT [5]. Patients are not traditionally evalu-
ated for bone lesions during routine staging due to the rare
presentation of these lesions without associated visceral
metastatic disease visible on CT imaging. In this case the
patient had multiple, significantly sized areas of bone
metastasis. The CT scan of these areas showed no visible
lesions. However, MRI visualized the sites of metastases
(Fig. 2). This demonstrates that CT may not be as sensitive
as MRI in detecting bone involvement in metastatic NSGCT.
In the study done by Hitchins [3], the CT scans of patients
with bone involvement were positive in seven out of eight
patients. Although only three patients underwent MRI, bone
lesions were visible in all three cases.
In conclusion, this case had a unique presentation of
a testicular NSGCT with skeletal metastases causingmatous germ cell tumor with bone metastasis only at diagnosis: A
doi.org/10.1016/j.ajur.2016.08.004
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AJUR120_proof ■ 30 August 2016 ■ 4/4symptomatic caudaequina syndrome, initially undetected
by routine staging. Although this is a rare finding, particu-
larly in the absence of concurrent nodal or visceral
metastases, it is important to evaluate patient with
NSGCT presenting with neurologic symptoms for bony and
spinal cord involvement. Additionally, it is important to
acknowledge that routine staging by CT scan may not al-
ways detect skeletal metastases of this disease, and MRI
should be considered as confirmative imaging when suspi-
cion warrants further investigation for lesions of the bone.
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